日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Neoantigen-specific CD4+ T cells in human melanoma have diverse differentiation states and correlate with CD8+ T cell, macrophage, and B cell function

人类黑色素瘤中新抗原特异性CD4+ T细胞具有多种分化状态,并与CD8+ T细胞、巨噬细胞和B细胞的功能相关。

Joshua R Veatch,Sylvia M Lee,Carolyn Shasha,Naina Singhi,Julia L Szeto,Ata S Moshiri,Teresa S Kim,Kimberly Smythe,Paul Kong,Matthew Fitzgibbon,Brenda Jesernig,Shailender Bhatia,Scott S Tykodi,Evan T Hall,David R Byrd,John A Thompson,Venu G Pillarisetty,Thomas Duhen,A McGarry Houghton,Evan Newell,Raphael Gottardo,Stanley R Riddell

A therapeutic cancer vaccine delivers antigens and adjuvants to lymphoid tissues using genetically modified T cells

治疗性癌症疫苗利用转基因 T 细胞将抗原和佐剂递送至淋巴组织

Joshua R Veatch, Naina Singhi, Shivani Srivastava, Julia L Szeto, Brenda Jesernig, Sylvia M Stull, Matthew Fitzgibbon, Megha Sarvothama, Sushma Yechan-Gunja, Scott E James, Stanley R Riddell

Mobilization of pre-existing polyclonal T cells specific to neoantigens but not self-antigens during treatment of a patient with melanoma with bempegaldesleukin and nivolumab

在用贝培加地白介素和纳武利尤单抗治疗黑色素瘤患者期间,可动员针对新抗原但不针对自身抗原的预先存在的多克隆T细胞

Veatch, Joshua R; Singhi, Naina; Jesernig, Brenda; Paulson, Kelly G; Zalevsky, Jonathan; Iaccucci, Ernesto; Tykodi, Scott S; Riddell, Stanley R

Endogenous CD4+ T Cells Recognize Neoantigens in Lung Cancer Patients, Including Recurrent Oncogenic KRAS and ERBB2 (Her2) Driver Mutations

内源性CD4+ T细胞可识别肺癌患者的新抗原,包括复发性致癌KRAS和ERBB2(Her2)驱动突变

Joshua R Veatch ,Brenda L Jesernig ,Julia Kargl ,Matthew Fitzgibbon ,Sylvia M Lee ,Christina Baik ,Renato Martins ,A McGarry Houghton ,Stanley R Riddell

Tumor-infiltrating BRAFV600E-specific CD4+ T cells correlated with complete clinical response in melanoma

肿瘤浸润性BRAFV600E特异性CD4+ T细胞与黑色素瘤的完全临床缓解相关

Veatch, Joshua R; Lee, Sylvia M; Fitzgibbon, Matthew; Chow, I-Ting; Jesernig, Brenda; Schmitt, Tom; Kong, Ying Ying; Kargl, Julia; Houghton, A McGarry; Thompson, John A; McIntosh, Martin; Kwok, William W; Riddell, Stanley R